Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iguratimod versus hydroxychloroquine for active systemic lupus erythematosus
ChiCTR2300067695Phase 4Recruiting
- Sponsor
- Third Xiangya Hospital, Central South University
- Start
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of iguratimod and hydroxychloroquine in systemic lupus erythematosus (SLE) (2 arms), sponsored by Third Xiangya Hospital, Central South University. Primary endpoints: Systemic lupus erythematosus response index, SLE Disease Activity Index 2000 score and 1 more. Started Jul 2020; status: recruiting.
02
Drugs
iguratimodhydroxychloroquine
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on ChiCTR2300067695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300067695.